

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

Security Agreement Termination and Release

CONVEYING PARTY DATA

Name	Execution Date
Denmerco Inc.	05/21/2004

RECEIVING PARTY DATA

Name:	EPiocyte Pharmaceutical, Inc.
Street Address:	158 Credle Street
Internal Address:	c/o Biolex, Inc., Attn: John Irick
City:	Pittsboro
State/Country:	NORTH CAROLINA
Postal Code:	27312

PROPERTY NUMBERS Total: 9

Property Type	Number
Application Number:	09005318
PCT Number:	US9800542
PCT Number:	US9800339
PCT Number:	US9822304
Patent Number:	6391280
Patent Number:	6440419
Patent Number:	6251392
Patent Number:	6045774
Application Number:	08782481

CORRESPONDENCE DATA

Fax Number: (919)821-6800

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 919-821-1220

Email: awagner@smithlaw.com

Correspondent Name: Ann B. Wagner, Paralegal

PATENT  
REEL: 014770 FRAME: 0324

OP \$360.00 09005318

Address Line 1:	2500 Wachovia Capitol Center
Address Line 2:	Smith Anderson
Address Line 4:	Raleigh, NORTH CAROLINA 27601

NAME OF SUBMITTER:	Ann B. Wagner
--------------------	---------------

Total Attachments: 3 source=termsecagmt#page1.tif source=termsecagmt#page2.tif source=termsecagmt#page3.tif
--

SECURITY AGREEMENT  
TERMINATION AND RELEASE

This Security Agreement Termination and Release (this "Termination") is made as of this 21st day of May 2004, by Denmerco Inc. ("Denmerco"), a Delaware corporation (as successor in interest to Dow Credit Corporation ("DCC"), a Delaware corporation).

R E C I T A L S

WHEREAS, pursuant to the terms of that certain Loan Agreement dated as of December 24, 2002 (the "Security Agreement"), between DCC and EPIcyte Pharmaceutical, Inc. (the "Company"), a California corporation, the Company granted to DCC a first priority security interest in all Collateral (as defined in the Security Agreement), including without limitation the patents and patent applications listed on Exhibit A attached hereto;

WHEREAS, pursuant to the terms of that certain Loan Assignment Agreement effective as of August 7, 2003 (the "Assignment Agreement"), between DCC and Denmerco, DCC transferred and assigned to Denmerco all of its interests, rights and obligations under the Security Agreement; and


WHEREAS, Denmerco desires to terminate the Security Agreement and release its security interest in the Collateral.

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, Denmerco does hereby covenant and agree as follows:

1. The Security Agreement, and Denmerco's security interest in the Collateral (including without limitation the patents and patent applications listed in Exhibit A), is hereby terminated and released.
2. Denmerco represents and warrants that it has full power and authority to execute this Termination and to release its security interest in the Collateral.
3. Denmerco represents and warrants that it has not assigned or otherwise encumbered its security interest in the Collateral.
4. Denmerco hereby agrees to execute, acknowledge and deliver all such further instruments and to take all such further actions as may be reasonably requested or are required to more fully and effectively carry out the purposes of this Termination.

IN WITNESS WHEREOF, Denmerco has duly executed this Termination  
as of the day and year first above written.

DENMERCO INC.  
a Delaware corporation

 By:   
Name: James H. Plonka  
Title: President

## EXHIBIT A

### Patents

#### Patent Nos.

6,391,280  
6,440,419  
6,251,392  
6,045,774

#### Patent Application Nos.

08/782,481  
09/005,318  
US98/00542  
US98/00339  
US98/22304